The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.
Haoran Li, Daniel Yick Chin Heng(University of Calgary), Hao‐Wen Sim(The University of Sydney), Connor Wells(Queen Mary University of London), Igor Stukalin(University of Calgary), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Hiral D. Parekh(Cleveland Clinic), Nils Kroeger(Universitätsmedizin Greifswald), Guillermo de Velasco(Dana-Farber Cancer Institute), Allan J. Pantuck(University of California System), Neeraj Agarwal(University of Utah), Jennifer J. Knox(National Cancer Center), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k